• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Up1.57% Nasdaq Up2.12%

    Sinovac Biotech Ltd. (SVA)

    5.92 Up 0.01(0.17%) 3:59PM EDT
    |After Hours : 5.90 Up 0.00 (0.04%) 4:00PM EDT - Nasdaq Real Time Price
    ProfileGet Profile for:
    Sinovac Biotech Ltd.
    No. 39 Shangdi Xi Road
    Haidian District
    Beijing, 100085
    China - Map
    Phone: 86 10 8289 0088
    Fax: 86 10 6296 6910
    Website: http://www.sinovac.com

    Index Membership:N/A
    Full Time Employees:646

    Business Summary 

    Sinovac Biotech Ltd., a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of vaccines against hepatitis A, hepatitis B, seasonal influenza, H5N1 and H1N1 pandemic influenza, and mumps in the People's Republic of China. Its marketed products include Healive, an inactivated hepatitis A vaccine; Bilive, a combined inactivated hepatitis A and B vaccine; Anflu, a split viron influenza vaccine; Panflu, a vaccine against the H5N1 influenza virus; Panflu.1, a vaccine against the influenza A H1N1 virus; mumps vaccine; and Split viron pandemic influenza vaccine. The company also develops the EV71 vaccine, which has completed Phase III clinical trial. In addition, it has completed pre-clinical studies for varicella, sabin inactivated polio, and hepatitis A and B vaccines; and focuses on commencing clinical trials for pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, and rubella vaccine. The company has a collaboration agreement with GlaxoSmithKline Biologicals SA to develop combination vaccines containing measles for the China market; Tianjin CanSino Biotechnology Inc. to develop a pneumococcal conjugate vaccine; and a license agreement with Medimmune, LLC to use patented reverse genetics technology pertaining to H5N1 influenza virus strain production for vaccines. Sinovac Biotech Ltd. was founded in 1999 and is headquartered in Beijing, the People's Republic of China.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Sinovac Biotech Ltd.

    Key Executives 
    Mr. Ming Xia , 42
    VP of Sales & Marketing
    Dr. Weidong Yin , 51
    Chairman, Chief Exec. Officer, Pres, Managing Director, Sec., Chairman of Sinovac Hong Kong, Chairman of Tangshan Yian, Chairman of Sinovac Dalian and Director of Sinovac Biotech Co
    Ms. Nan Wang , 50
    Chief Financial Officer and VP of Bus. Devel.
    Mr. Gao Qiang , 39
    VP of R&D
    Ms. Li Jing , 41
    VP of Quality and Production
    Amounts are as of Dec 31, 2006 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.